Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Outokumpu – Manager transaction: Martti Sassi

Outokumpu OyjStock exchange releaseManager transactionDecember 15, 2020 at 11.45 am EETOutokumpu – Manager transaction: Martti Sassi Outokumpu has received a notification from Martti Sassi, member of the Leadership Team, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given in the table below. Name of the manager Martti SassiPosition in the issuer Member of the Leadership TeamIssuer Outokumpu OyjIssuer’s LEI reference 5493009YRUJJDCFF0R80

Outokumpu – Manager transaction: Niklas Wass

Outokumpu OyjStock exchange releaseManager transactionDecember 15, 2020 at 11.45 am EETOutokumpu – Manager transaction: Niklas Wass Outokumpu has received a notification from Niklas Wass, member of the Leadership Team, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given in the table below. Name of the manager Niklas WassPosition in the issuer Member of the Leadership TeamIssuer Outokumpu OyjIssuer’s LEI reference 5493009YRUJJDCFF0R80Notification

Outokumpu – Manager transaction: Olli-Matti Saksi

Outokumpu OyjStock exchange releaseManager transactionDecember 15, 2020 at 11.45 am EETOutokumpu – Manager transaction: Olli-Matti Saksi Outokumpu has received a notification from Olli-Matti Saksi, member of the Leadership Team, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given in the table below. Name of the manager Olli-Matti SaksiPosition in the issuer Member of the Leadership TeamIssuer Outokumpu OyjIssuer’s LEI reference

Outokumpu – Manager transaction: Thomas Anstots

Outokumpu OyjStock exchange releaseManager transactionDecember 15, 2020 at 11.45 am EETOutokumpu – Manager transaction: Thomas Anstots Outokumpu has received a notification from Thomas Anstots, member of the Leadership Team, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information about the transaction is given in the table below. Name of the manager Thomas AnstotsPosition in the issuer Member of the Leadership TeamIssuer Outokumpu OyjIssuer’s LEI reference 5493009YRUJJDCFF0R80

Peab receives order located at Danderyd Hospital

Smidmek AB, a company in the Peab Group, has been commissioned to deliver the frame of a new building for Danderyd Hospital in Stockholm. The customer is Region Stockholm through Locum AB and the contract is worth SEK 169 million.Smidmek is complete supplier of prefabricated frames in steel and concrete. The new project is a divided contract for building 61 at Danderyd Hospital in which Smidmek will deliver the frame. The building will be around 34,000 m2 and have 14 floors with wards, clinics and a helicopter pad. The objective is to create a flexible building that can adapt to the

SpareBank 1 SR-Bank sign up to Poseidon Principles supporting the green shift in shipping

In the future, SpareBank 1 SR-Bank will place more importance on environmental standards when granting new loans to the shipping industry. In connection with this, SpareBank 1 SR-Bank have chosen to sign up to the so-called ‘Poseidon Principles’ initiative. This is a global framework where banks have joined forces to promote good, responsible environmental standards for customers within the shipping segment. SpareBank 1 SR-Bank are the 19th bank to sign up to this global framework aimining to achieve 50 per cent lower greenhouse gas emissions from shipping by 2050. - As part of this,

ProTrans Observation Study for long term efficacy in diabetes

NextCell Pharma AB (“NextCell” or “the Company”) today announces that an observational study, ProTrans-OBS, has been approved by the Swedish Ethical Review Board for long-term follow-up of patients previously participating in the ProTrans-2 clinical trial. The study is conducted by professor Per-Ola Carlsson, at Uppsala University.The observational study, ProTrans-OBS, is a non-interventional study, i.e.  patients will not be treated with additional doses of ProTrans. Participants that completed the ProTrans-2 trial will be asked for informed consent for biannual clinical assessment of

LightAir tests air purification technology against coronavirus

LightAir (LAIR, NGM) is initiating tests on coronavirus with a leading European virus research institute. The tests will show how well the Swedish company's IonFlow technology also prevents contact and airborne transmission of COVID19. A scientific study from Karolinska Institutet has previously shown that the technology inactivates influenza viruses immediately and continuously, and prevents airborne transmission.In the coming months, specific tests will be carried out to show how well IonFlow also neutralizes coronaviruses such as SARS-CoV-2, which causes the disease COVID19, and SARS-CoV-

H2Accelerate – new collaboration for zero emission hydrogen trucking at mass-market scale

Daimler Truck AG, IVECO, OMV, Shell and the Volvo Group today committed to work together to help create the conditions for the mass-market roll-out of hydrogen trucks in Europe.As a growing number of governments and businesses align on a common vision of a net-zero emissions energy system, the H2Accelerate participants believe that hydrogen is an essential fuel for the complete decarbonisation of the truck sector. Achieving a large-scale roll-out of hydrogen fuelled trucks is expected to create new industries: zero-carbon hydrogen production facilities, large-scale hydrogen distribution

Vestas signs agreement with Enel X to accelerate the electrification of its corporate fleet

Press Release from Vestas Wind Systems A/S and Enel XAarhus, 15 December 2020Vestas Wind Systems A/S, a world leader in sustainable energy solutions, signed a partnership with Enel X, the Enel Group’s advanced energy services business line, to accelerate the electrification of its company fleet. Through the agreement, Enel X will be providing Vestas with the required charging infrastructure to electrify its corporate fleet across its most prominent service markets. “If we are to succeed with the energy transition across a global scale, industry leaders have a duty to implement the

Citycon Oyj: Managers’ Transactions

CITYCON OYJ   Managers’ Transactions   15 December 2020 at 10:45 hrsThe acquisition of shares (in total 21,600) is based on the vesting period of 16 November 2019 to 15 November 2020 in the CEO Restricted Share Plan 2018‒2021. Person subject to the notification requirement: F. Scott Ball, CEOIssuer: Citycon Oyj, LEI 549300P8N0P6KDGTJ206Notification type: initial notificationReference number: 549300P8N0P6KDGTJ206_20201215091701_21) TransactionDate: 11 December 2020Venue: NASDAQ HELSINKI LTD (XHEL)Nature of the transaction: acquisitionInstrumentshare (CTY1S)ISIN Code:

Data showing high implant survival rate for Episealer® accepted for publication

Episurf Medical (Nasdaq: EPIS B) today announces that post-market surveillance survival data for the Episealer® Knee implant has been compiled and accepted for scientific publication in the peer-reviewed journal Surgical Technology International. The data shows a cumulative survival rate of >96% over 7 years. The publication, Patient-specific implants for focal cartilage lesions in the knee: implant survivorship analysis up to seven years post-implantation, by L. Ryd, K. Flodström and M. T. Manley focuses on survival data for 682 Episealer® knee implants implanted between 2012 and 2020. "

Risk Intelligence A/S records 0% churn and increases in license sizes in Q4 2020

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces 0% churn (100% renewal) as well as increases in license sizes and additional sales to existing clients in Q4 2020.Q4 is Risk Intelligence’s major annual renewal period for Risk Intelligence System licenses due to the large part of licenses that follow the calendar year, generating a strong base of recurring revenue for 2021. This year in Q4, 100% of Risk Intelligence System clients have renewed their licences, with several increasing the scope of the licence by adding more users or additional subscriptions to the

Correction: Metso Outotec's financial reporting in 2021

Metso Outotec Corporation’s stock exchange release on December 15, 2020, at 10:30 a.m. EETThis release replaces the stock exchange release published by Metso Outotec on December 14, at 9:00 a.m. EET, which included a wrong date for the publishing of the Financial Statements for 2020.Metso Outotec’s corrected dates for its financial reporting in 2021 are as follows.  · Financial Statements Review for 2020 on February 16, 2021 · Interim Report for January - March 2021 on April 23, 2021 · Half-Year Financial Report for January - June 2021 on August 4, 2021 · Interim Report

DOF ASA AND DOF SUBSEA AS: EXTENSION OF STANDSTILL ARRANGEMENT WITH BONDHOLDERS

Reference is made to the bondholders' meeting in DOFSUB07 (ISIN NO 001 0670144), DOFSUB08 (ISIN NO 001 078817.7) and DOFSUB09 (ISIN NO 001 083681.0) held on 30 September 2020 in accordance with the summons dated 16 September 2020, as amended by the addendum to the summons dated 30 September 2020. DOF Subsea AS has today received confirmation from the ad hoc group of bondholders that they have agreed to extend the suspension, deferral and standstill arrangement currently in place for the bond issue from 15 December 2020 to 31 January 2021 in accordance with the resolutions made at the

Cyxone has filed an IND in the US with Rabeximod following positive feed-back from pre-IND meeting with the FDA

Cyxone (publ.), a clinical stage biotech company developing first-in-class drugs for diseases of the immune system, announced today that the company has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) pertaining to its drug candidate Rabeximod. The application follows on a productive pre-IND meeting with the authority, where valuable advice was received on inter alia the protocol for its imminent European Phase 2 clinical study in moderate Covid-19. The IND covers the development of Rabeximod in Covid-19 and other indications, such as

DOCOMO Digital study reveals that the Covid-19 pandemic has accelerated the adoption of carrier billing

More than half of merchants consider working with a Direct Carrier Billing Specialist in 2021London, December 15, 2020 – A new study commissioned and sponsored by DOCOMO Digital, a global leader in direct carrier billing and alternative payments, reveals that the Covid-19 pandemic expedited the shift to carrier billing across global markets, with the majority of mobile operators surveyed identifying significant market opportunities to expand into new areas, some of which are not served by traditional payment methods. The study finds that approximately half of the respondents have or plan to

Changes and extensions to Relais Group Plc’s Facilities Agreement

Relais Group Plc Company Release 15.12. 2020 at 10.05 Changes and extensions to Relais Group Plc’s Facilities Agreement Relais Group Plc has agreed on extensions and amendments of its Facilities Agreement originally concluded in 2019 with its main bank. The Amended and Restated Facilities Agreement includes the refinancing of existing financing for corporate acquisitions and a new term loan facility of EUR 40 million for possible future corporate acquisitions. The Amended and Restated Facilities Agreement will remain in force until the end of May 2023. The maximum amount of

Half of Brits opt out of turkey this Christmas: sustainable food, relaxation and gifts with purpose on the menu this year

Kimberly Wyatt’s tips for a sustainable & stress-less ChristmasDespite the announcement of restrictions lifting over the festive period, over a third of us have decided to say goodbye to an indulgent Christmas and opt for a low-key, at home celebration, with relaxation, reading, family favourite foods and sustainable gifts top priority.One in four people are looking forward to not travelling anywhere for Christmas this year, with one in five planning a virtual gathering and a third of us avoiding the pre- Christmas crowds altogether by doing all their shopping online.The

Massive increase in testing capacity and pride of workmanship – the new Nokian Heavy Tyres R&D Center is up and running

Making professional tire use safer and more efficient sets high demands on product development. To bring new ideas to the market faster, testing has an important role. Nokian Tyres has invested heavily on a new, state-of-the-art test center for Nokian Heavy Tyres, upgrading the testing capabilities to a whole new level with added automation and capacity. Despite the challenges caused by the COVID-19 outbreak, the magic is already happening in the new building – enabling us to introduce more and better new heavy tires.   Due to Covid-19 restrictions, many phases of the construction

Lehto Group Plc: Managers’ Transactions

Lehto Group PlcManagers’ Transactions15 December 2020 at 10.00 (EET)Lehto Group Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Lehto, Hannu Position: Chief Executive Officer Issuer: Lehto Group Oyj LEI: 743700YEHY9I3ZDHNX66 Notification type: INITIAL NOTIFICATION Reference number: 743700YEHY9I3ZDHNX66_20201215094330_3 ____________________________________________ Transaction date: 2020-12-01 Venue: NASDAQ HELSINKI LTD (XHEL) Instrument type: FINANCIAL INSTRUMENT LINKED TO A

Financial Calendar for Panoro Energy ASA

FINANCIAL YEAR 2020 30.04.2021 – Annual Report 25.02.2021 – Quarterly Report – Q4   FINANCIAL YEAR 2021 25.08.2021 – Half-yearly Report27.05.2021 – Annual General Meeting 27.05.2021 – Quarterly Report – Q122.11.2021 – Quarterly Report – Q3   The Company holds a webcast presentation each quarter to discuss the results and operations. Event details are announced ahead of each quarterly results announcement. The information presented quarterly is also available on our website www.panoroenergy.com. Pursuant to the Norwegian Public Limited Liability Companies Act (

SCANDION ONCOLOGY ANNOUNCES OUTCOME IN THE RIGHTS ISSUE

Scandion Oncology A/S (“Scandion” or the “Company”) announces that the result of its rights issue (the “Rights Issue”), where the subscription period ended on December 10, 2020, shows that 3,600,363 shares, corresponding to approximately 34 percent of the shares offered, were subscribed for by exercise of subscription rights. Additionally, 1,634,048 shares, corresponding to approximately 15 percent of the Right Issue, were subscribed for without use of subscription rights, of which 1,318,505 shares, corresponding to 12 percent of the Rights Issue, were subscribed for by external professional

Nobina completes strategic acquisition of KE'S Bussar and strengthens its position in western Sweden

Nobina has entered an agreement to acquire the bus company Karl Erik Elofsson Buss Aktiebolag, domiciled in Kungsbacka, western Sweden. The acquisition strengthens Nobina’s position in western Sweden and broadens its contract portfolio, at the same time as there are new synergies between existing contracts, forthcoming tenders and bus-for-rail services. The acquisition encompasses a business with approximately 100 buses and 100 employees in tendered regular services and school bus services in addition to coach hire and bus-for-rail services. The transaction represents a continuation of Nobina’

There are no items matching the current filter
There are no more items matching the current filter
Back to top